The 4MOSC2 model tends to develop lymph node metastasis and is prone to resistance to ICI therapy, making it suitable for investigating the mechanisms of immunotherapy resistance.23 We further used the 4MOSC2 model to test the potential combination efficacy of LIMP-2 knockdown with αPD-1 therapy (Fig. 8b). Here, SCARB2 is linked to metastatic malignant neoplasm in the lymph nodes.